Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05223660Phase 1Completed

A Phase I Pharmacokinetics Study for KT07 Capsule

Role: lead

NCT04164121Phase 1Completed

A Clinical Study Trial of Phenlarmide in China

Role: lead

NCT04162275Phase 1Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Role: lead

NCT02867358Phase 2Completed

A Clinical Trial of KT07 Capsule in the U.S.A

Role: lead

NCT03235778Phase 1Completed

A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China

Role: lead

All 5 trials loaded